{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:12:58Z","timestamp":1789193578345,"version":"build-2803163510"},"reference-count":20,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"unspecified","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["microbone"],"award-info":[{"award-number":["microbone"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018857","name":"International Myeloma Society","doi-asserted-by":"publisher","award":["Translational Research Grant"],"award-info":[{"award-number":["Translational Research Grant"]}],"id":[{"id":"10.13039\/100018857","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EU HORIZON","award":["CERTAINTY"],"award-info":[{"award-number":["CERTAINTY"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,10,16]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>\n                    Targeting B-cell maturation antigen with chimeric antigen receptor (CAR) T-cells is a new standard of care in relapsed\/refractory multiple myeloma (RRMM). However, long-term data have currently remained sparse. In a recent study published in the\n                    <jats:italic>Journal for ImmunoTherapy of Cancer<\/jats:italic>\n                    by Jin\n                    <jats:italic>et al<\/jats:italic>\n                    , authors reported on a large cohort of 141 patients with a median follow-up of 20.2 months. They found an overall response rate of 90.1% with 48.2% achieving a complete response. The median progression-free survival was 15.2 months, and the 4-year overall survival rate was 63.2%. In the current article, we summarize the published long-term data from clinically approved and investigational CAR T-cells for RRMM.\n                  <\/jats:p>","DOI":"10.1136\/jitc-2025-012730","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T10:35:12Z","timestamp":1762511712000},"page":"e012730","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Mileage matters: long-distance performance of CARs in multiple myeloma"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct05430945","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Eric M","family":"Jurgens","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z","family":"Usmani","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2805-5973","authenticated-orcid":false,"given":"Maximilian","family":"Merz","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Leipzig University, Leipzig, Saxony, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"2026091123003409000_13.11.e012730.1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00933-8"},{"key":"2026091123003409000_13.11.e012730.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"2026091123003409000_13.11.e012730.3","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010687","article-title":"Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed\/refractory multiple myeloma","volume":"13","author":"Jin","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026091123003409000_13.11.e012730.4","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0681-6"},{"key":"2026091123003409000_13.11.e012730.5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-024-01530-z","article-title":"Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial","volume":"17","author":"Xu","year":"2024","journal-title":"J Hematol Oncol"},{"key":"2026091123003409000_13.11.e012730.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00760"},{"key":"2026091123003409000_13.11.e012730.7","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","article-title":"CARTITUDE-1 final results: Phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lin","year":"2023","journal-title":"JCO"},{"key":"2026091123003409000_13.11.e012730.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842"},{"key":"2026091123003409000_13.11.e012730.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"2026091123003409000_13.11.e012730.10","doi-asserted-by":"crossref","DOI":"10.1016\/S2152-2650(24)02346-2","article-title":"OA-65 Overall Survival (OS) With Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care (SoC) in Lenalidomide (Len)-Refractory Multiple Myeloma (MM): Phase 3 CARTITUDE-4 Study Update","volume":"24","author":"Mateos","year":"2024","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"key":"2026091123003409000_13.11.e012730.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309728"},{"key":"2026091123003409000_13.11.e012730.12","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/S2152-2650(24)01972-4","article-title":"P-069 Idecabtagene Vicleucel (ide-cel) in Patients (pts) with Triple-Class\u2013Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): the 5-year Follow-Up Analysis from KarMMa","volume":"24","author":"Anderson","year":"2024","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"key":"2026091123003409000_13.11.e012730.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614"},{"key":"2026091123003409000_13.11.e012730.14","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1182\/blood.2024024582","article-title":"Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses","volume":"144","author":"Ailawadhi","year":"2024","journal-title":"Blood"},{"key":"2026091123003409000_13.11.e012730.15","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1158\/1078-0432.CCR-24-0414","article-title":"A 5-Year Follow-up Clinical Study of the B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy HDS269B in Patients with Relapsed or Refractory Multiple Myeloma","volume":"30","author":"Chen","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026091123003409000_13.11.e012730.16","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.ymthe.2024.11.013","article-title":"Long-term safety and efficacy of the fully human CAR-T therapy CT103A in relapsed\/refractory multiple myeloma","volume":"33","author":"Yu","year":"2025","journal-title":"Mol Ther"},{"key":"2026091123003409000_13.11.e012730.17","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/ajh.26583","article-title":"CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed\/refractory multiple myeloma, including cases with poor performance status","volume":"97","author":"Du","year":"2022","journal-title":"Am J Hematol"},{"key":"2026091123003409000_13.11.e012730.18","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-60980-2","article-title":"Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma","volume":"16","author":"Atanackovic","year":"2025","journal-title":"Nat Commun"},{"key":"2026091123003409000_13.11.e012730.19","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1182\/blood-2022-166658","article-title":"Early and Sustained Undetectable Measurable Residual Disease (MRD) after Idecabtagene Vicleucel (ide-cel) Defines a Subset of Multiple Myeloma (MM) Patients in Karmma Achieving Prolonged Survival","volume":"140","author":"Paiva","year":"2022","journal-title":"Blood"},{"key":"2026091123003409000_13.11.e012730.20","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1158\/2643-3230.BCD-23-0044","article-title":"Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel","volume":"4","author":"Paiva","year":"2023","journal-title":"Blood Cancer Discov"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-012730","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:01:02Z","timestamp":1789192862000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-012730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":20,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,7]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/jitc-2025-012730"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-012730","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}